Get the Stockscreener App
104.88
0.76%
-0.80
Pre-market:
105.21
0.33
+0.31%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $104.88, with a volume of 7.12M.
It is down -0.76% in the last 24 hours and down -5.89% over the past month.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$105.68
Open:
$105.93
24h Volume:
7.12M
Relative Volume:
0.83
Market Cap:
$130.75B
Revenue:
$28.75B
Net Income/Loss:
$480.00M
P/E Ratio:
283.46
EPS:
0.37
Net Cash Flow:
$10.31B
1W Performance:
-0.35%
1M Performance:
-5.89%
6M Performance:
+20.90%
1Y Performance:
+55.82%
1-Day Range:
$104.35
$106.40
1-Week Range:
$99.25
$107.18
52-Week Range:
$62.07
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
104.88 | 130.75B | 28.75B | 480.00M | 10.31B | 0.37 |
|
LLY
Lilly Eli Co
|
734.90 | 660.07B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
153.91 | 344.63B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
171.68 | 303.70B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
62.88 | 279.13B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.58 | 216.43B | 51.72B | 11.94B | 13.81B | 5.88 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around - The Motley Fool
Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know - MSN
Gilead Sciences CFO sells $266,000 in stock - Investing.com
Gilead Sciences CFO sells $266,000 in stock By Investing.com - Investing.com India
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? - Yahoo Finance
Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now? - Insider Monkey
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
11 Most Undervalued Quality Stocks to Buy Now - Insider Monkey
Lobbying Update: $75,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Nasdaq
Goldman Sachs Adjusts Price Target on Gilead Sciences to $97 From $96, Maintains Neutral Rating - MarketScreener
Press Release Distribution & PR Platform - ACCESS Newswire
Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program - Yahoo Finance
Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price - simplywall.st
EPO board revives Gilead patent, sends case back for review - MLex
Gilead patent partially upheld by EPO, Teva and STADA's challenge continues - MLex
Here's What to Expect From Gilead Sciences’ Next Earnings Report - Nasdaq
Gilead reprimanded after PMCPA finds conference Wi-Fi sponsorship broke advertising rules - Fierce Pharma
Here's What To Expect From Gilead Sciences’ Next Earnings Report - Barchart.com
Gilead Sciences, Trusaic Data Breach Lawsuit Investigation - ClassAction.org
PatientView Ranks Gilead “Best” at ESG - CSRwire
Gilead Sciences Inc (GILD) Shares Gap Down to $100.87 on Apr 10 - GuruFocus
Gilead Sciences To Release First Quarter 2025 Financial Results On Thursday, April 24, 2025 - MarketScreener
Gilead Sciences Announces Q1 Estimated Acquired IPR&D - MarketScreener
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 | GILD Stock News - GuruFocus
Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025 - Business Wire
AI-startup Prezent names Gilead Sciences’ exec to Board - StartUp Beat
PatientView Ranks Gilead "Best" at ESG - MarketScreener
Gilead is urged to rework licensing deals for groundbreaking HIV prevention drug - statnews.com
Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy - MarketScreener
Manufacturer’s plans for equitable access to twice-yearly PrEP under fire - Aidsmap
Mich. Panel: Gilead Immune From Recalled COVID Drug Suit - Law360
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Gilead, Michigan Hospital Win Appeal Over Tainted Covid-19 Drug - Bloomberg Law News
Gilead Sciences (GILD) Anticipates Earnings Surprise - GuruFocus
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States - Gilead Sciences
Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1 - Insider Monkey
Weekly CFO Sells Highlight: Adobe Systems, Gilead Sciences and A - GuruFocus
July 18th Options Now Available For Gilead Sciences (GILD) - Nasdaq
Gilead Sciences describes new nucleoside prodrugs for viral infections - BioWorld MedTech
Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections - ACCESS Newswire
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
In Bay Area, Gilead cuts 149 positions and Roche's diagnostics division lays off 108 - Fierce Pharma
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? - Nasdaq
Optimistic Growth Prospects for Gilead Sciences: Buy Rating Backed by HIV and Oncology Advancements - TipRanks
Gilead Sciences - drugdiscoverytrends.com
The Centrifuge Sessions: Driving Innovation and Investment in Cancer Research - CSRwire
Gilead, Roche to eliminate over 250 Bay Area jobs - FirstWord Pharma
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities - ACCESS Newswire
Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Gilead: HIV Franchise Woes Highlight Cancer Follies - Seeking Alpha
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):